AMI Cardiogenic Shock
Clinical Evidence
AMI Cardiogenic Shock

Clinical Evidence

Key Findings from the National Cardiogenic Shock Initiative Study1,2,3

  • Identify and support cardiogenic shock early
  • Turn down titriation of inotropes aggressively
  • Identify inadequate left ventricular (LV) support and escalate, if CPO <0.6
  • Identify right ventricular (RV) dysfunction early and support
  • Systematically use right heart catheter (RHC) to guide therapy

Clinical Evidence of Impella® Systems: Pathway to Class I Recommendation

Clinical evidence of Impella systems has established safety and effectiveness and validated best practices.

Ongoing and Upcoming Clinical Trials

RECOVER IV Randomized Controlled Trial

Upcoming trial to assess whether Impella pre-PCI is superior to PCI without Impella in patients with AMI cardiogenic shock.

NSCI Study

Ongoing trial seeking to improve mortality in patients with AMI cardiogenic shock using the NCSI algorithm.

DanGer Shock Randomized Controlled Trial

Ongoing trial assessing primary outcome of death from all causes at six months with Impella CP® heart pump compared to standard of care.

The Procedure

Learn more about femoral access, explant techniques and other best practises.

References

  1. Tehrani, B.N., et al. (2019). JACC. 73, 1659-1669.
  2. Basir, M.B., et al. (2019). Catheter Cardiovasc Interv, 93(7), 1173-1183.
  3. O’Neill, W.W., TCT 2020.

NPS-2632

The Protected PCI community
is now on HeartRecovery.com

Providing education and training to help health care professionals
recover hearts, oxygenate the body and save lives.
Explore Now